University of California, VA Medical Center, Center for Neuroimaging of Neurodegenerative Diseases , San Francisco, San Francisco, CA 94121, USA.
Neurobiol Aging. 2012 Aug;33(8):1599-608. doi: 10.1016/j.neurobiolaging.2011.05.005. Epub 2011 Jun 17.
Weight changes are common in aging and Alzheimer's disease (AD) and postmortem findings suggest a relation between lower body mass index (BMI) and increased AD brain pathology. In the current multicenter study, we tested whether lower BMI is associated with higher core AD brain pathology as assessed by cerebrospinal fluid (CSF)-based biological markers of AD in 751 living subjects: 308 patients with AD, 296 subjects with amnestic mild cognitive impairment (MCI), and 147 elderly healthy controls (HC). Based upon a priori cutoff values on CSF concentration of total tau and beta-amyloid (Aβ(1-42)), subjects were binarized into a group with abnormal CSF biomarker signature (CSF+) and those without (CSF-). Results showed that BMI was significantly lower in the CSF+ when compared with the CSF- group (F = 27.7, df = 746, p < 0.001). There was no interaction between CSF signature and diagnosis or apolipoprotein E (ApoE) genotype. In conclusion, lower BMI is indicative of AD pathology as assessed with CSF-based biomarkers in demented and nondemented elderly subjects.
体重变化在衰老和阿尔茨海默病（AD）中很常见，尸检结果表明，较低的体重指数（BMI）与 AD 大脑病理增加之间存在关系。在当前的多中心研究中，我们测试了 751 名存活受试者的脑脊液（CSF）AD 生物标志物评估的核心 AD 大脑病理是否与较低的 BMI 相关：308 名 AD 患者，296 名遗忘型轻度认知障碍（MCI）患者和 147 名老年健康对照者（HC）。基于 CSF 中总 tau 和 β-淀粉样蛋白（Aβ（1-42）浓度的预先确定的截断值，受试者被二分为 CSF 生物标志物特征异常（CSF+）和无异常组（CSF-）。结果表明，与 CSF-组相比，CSF+组的 BMI 明显降低（F = 27.7，df = 746，p < 0.001）。CSF 特征与诊断或载脂蛋白 E（ApoE）基因型之间没有相互作用。总之，在痴呆和非痴呆老年受试者中，较低的 BMI 是 CSF 生物标志物评估 AD 病理的指标。
